Company news

Nkarta, Inc. news in 2021

Nkarta, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML

December 15, 2021

Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition

December 12, 2021

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

November 11, 2021

Nkarta Reports Third Quarter 2021 Financial Results and Business Update

November 9, 2021

Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs

October 6, 2021

Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

September 30, 2021

Nkarta Reports Second Quarter 2021 Financial Results and Business Progress

August 11, 2021

Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters

July 13, 2021

Nkarta to Present at Upcoming Investor Conference

June 15, 2021

Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term

June 13, 2021

Nkarta Announces June 2021 Investor Conference Schedule

May 24, 2021

Nkarta Reports First Quarter 2021 Financial Results and Business Progress

May 12, 2021

CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer

May 5, 2021

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

April 27, 2021

Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress

March 24, 2021

Nkarta Announces February and March 2021 Investor Conference Schedule

February 16, 2021

Decks in 2021